Exhibit 99.1
CONTACT: |
|
|
|
|
|
VIVUS, Inc. |
| Trout Group |
Timothy E. Morris |
| Ian Clements (SF) 415-392-3385 |
Chief Financial Officer |
| Brian Korb (NYC) 646-378-2923 |
650-934-5200 |
|
|
FOR IMMEDIATE RELEASE
VIVUS TO PRESENT AT THE 2008 MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Mountain View, Calif, February 1, 2008—VIVUS, Inc (NASDAQ: VVUS) a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Leland F. Wilson, President and CEO, will present an overview of the company at the 19th Annual Merrill Lynch Global Pharmaceutical, Biotechnology, and Medical Device Conference in New York City.
The VIVUS presentation will take place at the Grand Hyatt Hotel in New York on Thursday, February 7, 2008 at 1:40 p.m. ET. A live audio webcast and 14-day archive of the presentation will be available at http://ir.vivus.com.
About VIVUS
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products. The current portfolio includes investigational products addressing obesity and sexual health. The pipeline includes: Qnexa™, which is in phase 3 for the treatment of obesity and phase 2 for the treatment of type 2 diabetes; Testosterone MDTS®, for which a phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, for which a phase 2 study has been completed for the treatment of erectile dysfunction (ED). For more information on clinical trials and products, please visit the company’s web site at http://www.vivus.com.
###